Axial spondyloarthritis and its subtypes
Axial spondyloarthritis* (axSpA) is a chronic inflammatory condition consisting of two subtypes, non-radiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS). They have shared symptoms, including spinal pain, reduced mobility, and fatigue.
Signs and symptoms of axSpA include:
- Morning back pain and stiffness
- Spinal inflammation
- Pain in lower back and hips
- Reduced physical function
- Less mobility
What makes AS and nr-axSpA different from back pain?
- Common back pain is typically caused by injury or overuse and usually goes away after 6 weeks; any longer and it may be something more serious
- AS and nr-axSpA are types of chronic, inflammatory back pain
- AS and nr-axSpA occur when the immune system mistakenly attacks healthy joints, mainly in the spine
- Symptoms may last for 3 months or longer, and can flare on and off
- Although AS and nr-axSpA are lifelong conditions, there are many ways to manage them
What makes AS different from nr-axSpA?
Both AS and nr-axSpA, subtypes of axial spondyloarthritis (axSpA), are chronic inflammatory rheumatic diseases that primarily affect the spine with some notable differences:
- With AS, joint damage is clearly visible on an X-ray, but this is not always the case with nr-axSpa
- The male-to-female ratio of people with AS is 3:1, but with nr-axSpA, the ratio is 1:1
- While both present differently in everyone, AS tends to impact men in the lower back and buttocks, and impacts women more in the hips, neck, shoulders, and knees
- With nr-axSpA, women typically have more widespread pain that can lead to a delayed diagnosis compared to men
How does Taltz work for patients with axial spondyloarthritis?
Taltz is a treatment that targets and blocks interleukin-17A (IL-17A),* which is a protein in your body. Elevated levels of interleukin-17A (IL-17A) are associated with inflammation of the spine and can lead to symptoms of axSpA such as back pain, inflammation, fatigue, and difficulty carrying out daily activities.
Taltz is approved to treat adults with active ankylosing spondylitis (AS) and adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation.